Jose Conejo-Garcia @conejo-garcia.bsky.social · 05/10/2026www.prnewswire.com/news-release... Anixa Biosciences Announces First Case of Stable Disease for Three Months in Ovarian Cancer CAR-T Clinical Trial evaluating its novel FSHR-targeted CAR-T therapy for recurrent ovarian cancer.prnewswire.com 000
Jose Conejo-Garcia @conejo-garcia.bsky.social · 24/08/2026Anixa Biosciences to Present at the 2026 Cantor Fitzgerald Global Healthcare Conference Highlighting its Ovarian Cancer CAR-T Therapy ir.anixa.com/press-releas...ir.anixa.comPress Releases :: Anixa Biosciences, Inc. (ANIX) 000
Jose Conejo-Garcia @conejo-garcia.bsky.social · 21/08/2026Registration for the Ovarian Cancer Midwest Focus Conference is open (Rochester, MN, November 2-3): www.ocmfconference.com/registrationocmfconference.com2026 Registration | OCMF 000
Jose Conejo-Garcia @conejo-garcia.bsky.social · 03/08/2026The American Association of Immunologists (AAI) is appalled by the continuing efforts to target Anthony S. Fauci, MD, AAI member and one of the nation’s most accomplished physician-scientists and a longstanding member of the immunology community. news.aai.org/2026/08/03/a...news.aai.org 000
Reposted by Jose Conejo-GarciaCancer Cell @cp-cancercell.bsky.social · 28/07/2026Online Now: Tumor-infiltrating plasma cell profiling after PD-1 blockade reveals tumor-specific antibodiesdlvr.itTumor-infiltrating plasma cell profiling after PD-1 blockade reveals tumor-specific antibodiesMeyerhoff et al. identify tumor-infiltrating plasma cells as a source of antibodies with therapeutic potential. Their lead antibody, PC-1, recognizes citrullinated antigens on cancer and tumor-promoting myeloid cells and can be repurposed to guide CAR T cell therapy. 033
Reposted by Jose Conejo-GarciaJose Conejo-Garcia @conejo-garcia.bsky.social · 27/07/2026Tumor-infiltrating plasma cell profiling after PD-1 blockade reveals tumor-specific antibodies: Cancer Cell www.cell.com/cancer-cell/...cell.comTumor-infiltrating plasma cell profiling after PD-1 blockade reveals tumor-specific antibodiesMeyerhoff et al. identify tumor-infiltrating plasma cells as a source of antibodies with therapeutic potential. Their lead antibody, PC-1, recognizes citrullinated antigens on cancer and tumor-promoti... 001
Jose Conejo-Garcia @conejo-garcia.bsky.social · 27/07/2026Tumor-infiltrating plasma cell profiling after PD-1 blockade reveals tumor-specific antibodies: Cancer Cell www.cell.com/cancer-cell/...cell.comTumor-infiltrating plasma cell profiling after PD-1 blockade reveals tumor-specific antibodiesMeyerhoff et al. identify tumor-infiltrating plasma cells as a source of antibodies with therapeutic potential. Their lead antibody, PC-1, recognizes citrullinated antigens on cancer and tumor-promoti... 001
Jose Conejo-Garcia @conejo-garcia.bsky.social · 14/07/2026Ovarian cancer tumor immune profiles associated with intrauterine device and oral contraceptive use rdcu.be/ftJ6drdcu.beOvarian cancer tumor immune profiles associated with intrauterine device and oral contraceptive useBritish Journal of Cancer - Ovarian cancer tumor immune profiles associated with intrauterine device and oral contraceptive use 000
Jose Conejo-Garcia @conejo-garcia.bsky.social · 12/07/2026Isotype-switched antibodies originating from tertiary lymphoid structures can antagonize ovarian cancer progression: iScience www.cell.com/iscience/ful... 000
Jose Conejo-Garcia @conejo-garcia.bsky.social · 06/07/2026Anixa Biosciences and Moffitt Cancer Center Advance Ovarian Cancer CAR-T Clinical Trial to Highest Dose Level to Date Full press release: ir.anixa.com/press-releas...ir.anixa.comPress Releases :: Anixa Biosciences, Inc. (ANIX) 000
Jose Conejo-Garcia @conejo-garcia.bsky.social · 23/06/2026CARsgen Announces Approval of Satri-cel, the World's First CAR T-Cell Therapy Product for Solid Tumors www.prnewswire.com/news-release... 000
Jose Conejo-Garcia @conejo-garcia.bsky.social · 18/06/2026The 2026 Lotus Award winners with Bill Ackman (from left to right): Richard Gregory (UMass), Jose Conejo-Garcia (Duke), Tal Danino (Columbia), Ernst Lengyel (U. Chicago), Scott Lowe (Memorial Sloan Kettering), Swarnali Acharyya (Columbia), and Dan Landau (Cornell) 000
Jose Conejo-Garcia @conejo-garcia.bsky.social · 13/06/2026Atezolizumab in combination with neoadjuvant chemotherapy and interval cytoreductive surgery for patients with newly diagnosed advanced-stage epithelial ovarian cancer: the AdORN study pubmed.ncbi.nlm.nih.gov/42284713/ 000
Jose Conejo-Garcia @conejo-garcia.bsky.social · 03/06/2026Another red alert for American science | Science www.science.org/doi/10.1126/...science.orgAnother red alert for American scienceAlthough research has bipartisan support in the US Congress, and trust in science is above 75% across the country, the Trump administration seems as determined as ever to mortally wound the nation’s s... 000
Jose Conejo-Garcia @conejo-garcia.bsky.social · 01/06/20268th Annual Ovarian Cancer Midwest Focus (OCMF) Conference, November 2-3, Rochester, MN Registration:https://www.ocmfconference.com/registration Abstract submission:https://docs.google.com/forms/d/e/1FAIpQLSfddMLDh4-C4ZaN6YK6ZgSLgNp8G5662vd8-oWy9e6pNua1Rw/viewform 000
Jose Conejo-Garcia @conejo-garcia.bsky.social · 01/06/2026Spatially Defined Cellular Niches Forged by Tumor-Intrinsic MHCII Redefine Immune Competence in Ovarian Cancer aacrjournals.org/cancerdiscov...aacrjournals.orgSpatially Defined Cellular Niches Forged by Tumor-Intrinsic MHCII Redefine Immune Competence in Ovarian CancerSummary:. Using integrated multiomic and spatially resolved single-cell profiling of high-grade serous ovarian cancer, Perez-Villatoro and colleagues show that tumor cell–intrinsic MHC class II (MHCII... 000
Jose Conejo-Garcia @conejo-garcia.bsky.social · 30/05/2026local.newsbreak.com/tampa-bay-ti... "John Cleveland, a Moffitt executive vice president, will take over Flores’s position as associate center director. Her role as division chief will be handled by Kenneth Wright, Moffitt’s associate center director of research education and training." 000
Jose Conejo-Garcia @conejo-garcia.bsky.social · 30/05/2026Moffitt executive resigns leadership role after investigation of her research www.tampabay.com/news/health/... 2100
Jose Conejo-Garcia @conejo-garcia.bsky.social · 29/05/2026The Pershing Square Foundation Announces Its 2026 Lotus Award Recipients - www.businesswire.com/news/home/20...businesswire.com 000
Jose Conejo-Garcia @conejo-garcia.bsky.social · 29/05/2026The Pershing Square Foundation Announces Its 2026 Lotus Award Recipients — Pershing Square Philanthropies pershingsquarephilanthropies.orgpershingsquarephilanthropies.orgPershing Square Philanthropies | Risk Capital for Philanthropy — Pershing Square PhilanthropiesPershing Square Philanthropies bets on innovative leaders solving humanity’s big societal, environmental, and health challenges. Learn more. 000
Jose Conejo-Garcia @conejo-garcia.bsky.social · 11/05/2026Anixa Biosciences Reports Updated Positive Survival Observations from Ongoing Phase 1 Trial of Lira-cel Ovarian Cancer CAR-T Therapy ir.anixa.com/press-releas...ir.anixa.comPress Releases :: Anixa Biosciences, Inc. (ANIX) 000
Reposted by Jose Conejo-Garciaallen institute @alleninstitute.org · 01/05/2026Happy Birthday to Santiago Ramón y Cajal - the "father of modern neuroscience." 110735
Jose Conejo-Garcia @conejo-garcia.bsky.social · 01/05/2026Single-cell spatial atlas of high-grade serous ovarian cancer uncovers MHC class II as a key predictor of spatial tumor ecosystems and clinical outcomes aacrjournals.org/cancerdiscov...aacrjournals.orgSingle-cell spatial atlas of high-grade serous ovarian cancer uncovers MHC class II as a key predictor of spatial tumor ecosystems and clinical outcomesAbstract. The tumor microenvironment in high-grade serous ovarian carcinoma (HGSC) is a complex network of malignant–host cell interactions, yet its orchestration remains poorly understood. We present... 000
Jose Conejo-Garcia @conejo-garcia.bsky.social · 21/04/2026Sobering piece about the devastating consequences of conspiracy theories-driven vaccine hesitation: Measles Took My Daughter. This Is What I Want Everyone to Know. www.nytimes.com/2026/04/21/o...nytimes.comOpinion | Measles Took My Daughter. This Is What I Want Everyone to Know. 000
Jose Conejo-Garcia @conejo-garcia.bsky.social · 19/04/2026www.nature.com/articles/s41... Should researchers avoid translational research in animals in favor of human models? We argue that this debate should focus on how experimental systems can be combined to maximize mechanistic confidence, human relevance, and real-world decision-making value. 000
Jose Conejo-Garcia @conejo-garcia.bsky.social · 13/04/2026Advances in ovarian cancer research and treatment made over the last decade, plus current challenges, emerging technologies in prevention, early detection, and treatment, and research priorities for the years ahead in press at Nature Reviews in Cancer: rdcu.be/fdbBordcu.beRethinking ovarian cancer III: the past decade and future directionsNature Reviews Cancer - In this Expert Recommendation, Bowtell and colleagues outline progress made over the last decade in the research and treatment of high-grade serous carcinoma as well as... 000
Jose Conejo-Garcia @conejo-garcia.bsky.social · 12/04/2026I’m a Nobel Prize-winning immigrant. I can no longer recognize this country. open.substack.com/pub/ofthebra...open.substack.comI’m a Nobel Prize-winning immigrant. I can no longer recognize this country.Attacks on science and immigrants are destroying America. 000
Jose Conejo-Garcia @conejo-garcia.bsky.social · 09/04/2026The biennial RIVKIN ovarian cancer symposium will take place in Philly on October 16-18. Abstracts are accepted from April 14 to July 14 000
Jose Conejo-Garcia @conejo-garcia.bsky.social · 06/04/2026Dr. Amit Kumar, CEO of Anixa Biosciences, discusses on new CAR T cell technologies to treat ovarian cancer FSH-directed CER T cells) and a vaccine against breast cancer www.youtube.com/watch?v=96uS...youtube.comThis CEO Is Creating A Vaccine To Cure Breast Cancer - Meet Dr. Amit Kumar, CEO of Anixa BiosciencesYouTube video by Smart Money Circle Show Hosted By Adam Sarhan 000
Jose Conejo-Garcia @conejo-garcia.bsky.social · 31/03/2026A new study from Ron Buckanovich and colleagues using a human stroma-patient-derived xenograft tumor model demonstrates the impact of human tumor stroma on recruitment of TAMs and tumor immune exclusion, which alters the response to immunotherapy. rdcu.be/fa3Sordcu.beA novel humanized immune stroma PDX cancer model for therapeutic studies 010
Jose Conejo-Garcia @conejo-garcia.bsky.social · 03/03/2026The 16th Biennial Rivkin Ovarian Cancer Research Symposium will take place on October 16-18, 2026 at the Sheraton Philadelphia Downtown in Philadelphia, PA. ocrahope.org/research/riv...ocrahope.orgRivkin Ovarian Cancer Research Symposium | OCRAOvarian Cancer Research Alliance is proud to present the 16th Biennial Rivkin Ovarian Cancer Research Symposium. October 16-18, 2026 in Philadelphia, PA. 000
Jose Conejo-Garcia @conejo-garcia.bsky.social · 09/02/2026Anixa Biosciences Reports Encouraging Patient Survival Observations in Ovarian Cancer CAR-T Trial; Achieves Regulatory Approval Enabling Major Dose Escalation ir.anixa.com/press-releas...ir.anixa.comPress Releases :: Anixa Biosciences, Inc. (ANIX) 000
Jose Conejo-Garcia @conejo-garcia.bsky.social · 02/02/2026Anixa Biosciences Secures United States Adopted Names Council Approval of Non-Proprietary Name for its CAR-T Therapy, a Key Step Toward Future Commercialization ir.anixa.com/press-releas...ir.anixa.comPress Releases :: Anixa Biosciences, Inc. (ANIX) 000
Jose Conejo-Garcia @conejo-garcia.bsky.social · 29/01/2026Beautiful study by Sungjune Kim and Imene Hamaidi at Mayo on how SIRT2-driven LCK acetylation elevates the threshold of TCR activation, which can be targeted with inhibitors and genetic approaches in real world tumor-reactive TILs. True immunology: rdcu.be/e1iSArdcu.beSIRT2-mediated deacetylation of LCK governs the magnitude of T cell receptor signalingNature Immunology - Phosphorylation-dephosphorylation and ubiquitination tune TCR signaling to avoid self-reactivity. Kim and colleagues show that acetylation also modulates TCR signaling. 000
Jose Conejo-Garcia @conejo-garcia.bsky.social · 20/11/2025Great story from Carlos Ontiveros and Tyler Curiel on the role opf PD-L2 in anti-tumor immunity in old subjects with melanoma. PD-L1 and PD-1 blockade are often equated but biologically it is not the same and they may have different clinical applications. rdcu.be/eQWiwrdcu.beAnti-PD-L2 immunotherapy is efficacious against melanoma in aged hosts through IL-17 and IFNγ signallingNature Communications - PD-L2 can bind the immune checkpoint PD-1. However, its potential as a therapeutic target for immune checkpoint blockade in cancer has not been extensively explored. Here,... 010
Jose Conejo-Garcia @conejo-garcia.bsky.social · 17/11/2025Anixa Biosciences Announces World Health Organization (WHO) Approval of International Non-Proprietary Name for its CAR-T Therapy, Marking a Key Milestone Toward Global Recognition and Future Commercialization: ir.anixa.com/press-releas...ir.anixa.comPress Releases :: Anixa Biosciences, Inc. (ANIX) 000
Jose Conejo-Garcia @conejo-garcia.bsky.social · 14/11/2025The promise of TIL therapy for glioblastoma. Inspiring perspective from Mustafa Kharaw's team on their ongoing work to make immunotherapy effective against one of the most devastating human cancers: www.sciencedirect.com/science/arti...sciencedirect.comThe promise of TIL therapy for glioblastomaTumor-infiltrating lymphocyte (TIL) therapy has demonstrated efficacy in refractory melanoma and durable responses in lung cancer. Glioblastoma presen… 000
Jose Conejo-Garcia @conejo-garcia.bsky.social · 10/11/2025Anixa Biosciences, Inc. (ANIX), which is testing CER T cells redirected against FSHR with FSH in patients with relapsed, chemoresisatnt ovarian cancer, will participate in the upcoming Water Tower Research Fireside Chat Series (November 11, 2025, at 11:00am PT) us06web.zoom.us/webinar/regi...us06web.zoom.usWelcome! You are invited to join a webinar: Fireside Chat: Anixa Biosciences, Inc. (ANIX) . After registering, you will receive a confirmation email about joining the webinar.Please join us for a conversation with Chairman & CEO Dr. Amit Kumar, PhD, on Tuesday, November 11, 2025, at 2:00 pm ET. Our topics of discussion will cover: • An overview of clinical development pro... 000
Jose Conejo-Garcia @conejo-garcia.bsky.social · 03/11/2025Leukocyte-intrinsic ER stress responses contribute to chemotherapy-induced peripheral neuropathy | Science Translational Medicine www.science.org/doi/10.1126/...science.orgLeukocyte-intrinsic ER stress responses contribute to chemotherapy-induced peripheral neuropathyDepletion of the ER stress sensor IRE1α can reduce paclitaxel-induced peripheral neuropathy in mice. 000
Jose Conejo-Garcia @conejo-garcia.bsky.social · 06/10/2025Medicine Nobel for researchers who characterized the immunobiology of regulatory T cells (previously "suppressor T cells"): www.science.org/content/arti...science.orgMedicine Nobel for researchers who discovered immune system's security guardsMary Brunkow, Fred Ramsdell, Shimon Sakaguchi honored for research on ‘peripheral immune tolerance’ 000
Jose Conejo-Garcia @conejo-garcia.bsky.social · 11/09/2025working group report from the 2024 National Cancer Institute / Gynecologic Cancer Steering Committee endometrial cancer clinical trials planning meeting: refining the approach to endometrial cancer in the immunotherapy era url: academic.oup.com/jnci/article...academic.oup.comA working group report from the 2024 National Cancer Institute / Gynecologic Cancer Steering Committee endometrial cancer clinical trials planning meeting: refining the approach to endometrial cancer ...Abstract. Endometrial cancer is now the leading cause of gynecologic cancer death in the United States. Recognizing the urgent need to improve outcomes for 000
Jose Conejo-Garcia @conejo-garcia.bsky.social · 12/08/2025Anixa Biosciences Announces Issuance of Additional U.S. Patent for CAR-T Technology: ir.anixa.com/press-releas... 000
Jose Conejo-Garcia @conejo-garcia.bsky.social · 11/08/2025Immune memory shapes ovarian cancer recurrence: Comment on the article of Ghisoni and Dangaj in Cancer Cell www.cell.com/cancer-cell/...cell.comImmune memory shapes ovarian cancer recurrenceDespite current progress, many patients with ovarian cancer (OC) often relapse after therapy. In this issue of Cancer Cell, Ghisoni et al. integrate multiomic and functional analyses to provide a road... 000
Jose Conejo-Garcia @conejo-garcia.bsky.social · 08/08/2025Dr. Robert Wenham, principal investigator for Anixa's ongoing ovarian cancer CAR-T therapy Phase 1 clinical trial, will be presenting at the 13th Annual Ovarcoming Cancer Conference, being held September 18 – 19, 2025, at the Briar Club in Houston, Texas. ir.anixa.com/press-releas... 010
Jose Conejo-Garcia @conejo-garcia.bsky.social · 31/07/2025This new study from Dangaj& Ghisoni in Cancer Cell analyzed 131 matching primary/relapsed ovarian cancers, to show that the immune landscape of the original tumor is re-established in the recurrent lesion, which depends on HRD status and pre-existing TIL:myeloid niches. www.cell.com/cancer-cell/...cell.comMyeloid cell networks govern re-establishment of original immune landscapes in recurrent ovarian cancerGhisoni et al. profile the immune landscape of 697 ovarian cancers (OCs), identifying four immune phenotypes linked to prognosis and treatment response. The study demonstrates that BRCA-dependent TIL:... 141
Jose Conejo-Garcia @conejo-garcia.bsky.social · 31/07/2025Federal government freezes $108 million in NIH funding to Duke. Apparently for racial discrimination...against white Anglos in the Deep South...this sounds like a Tarantino movie... www.dukechronicle.com/article/2025...dukechronicle.comFederal government freezes $108 million in NIH funding to Duke, source tells The ChronicleThe freeze follows two federal investigations launched Monday by the Trump administration into Duke University and Duke Health, alleging “systemic racial discrimination” and violations of the Civil Ri... 000
Jose Conejo-Garcia @conejo-garcia.bsky.social · 24/07/2025In this new study, Aaron Ring and colleagues demonstrate the importance of antibody responses on the effectiveness of patients with cancer treated with ICI. As for treatment naive tumors, these are autoandibodies thsat in most cases do not cause autoimmunity: rdcu.be/exGyTrdcu.beHumoral determinants of checkpoint immunotherapyNature - Rapid extracellular antibody profiling reveals a contribution of autoantibodies to the effectiveness of checkpoint immunotherapy for cancer. 041
Jose Conejo-Garcia @conejo-garcia.bsky.social · 09/07/2025Improving lung cancer tumor infiltrating lymphocytes (TILs) manufacturing - Cytotherapy www.isct-cytotherapy.org/article/S146...isct-cytotherapy.orgImproving lung cancer tumor infiltrating lymphocytes (TILs) manufacturingThe successful treatment of melanoma using autologous in-vitro expanded tumor infiltrating lymphocytes (TILs) has sparked clinical trials for the assessment of TILs efficacy against other cancers, inc... 000
Jose Conejo-Garcia @conejo-garcia.bsky.social · 08/07/2025NIH announces end to funding for animal-only studies. This is potentially catastrophic. www.drugdiscoverytrends.com/nih-announce...drugdiscoverytrends.comNIH announces end to funding for animal-only studies - Drug Discovery and DevelopmentDrug Discovery and Development covers strategies and technologies related to pharmaceutical research and development and drug formulation. 110
Jose Conejo-Garcia @conejo-garcia.bsky.social · 07/07/2025Zelig Eshhar, leading cancer researcher and immunologist, and the father of CAR T cells, dies at 84: www.timesofisrael.com/zelig-eshhar...timesofisrael.comZelig Eshhar, leading cancer researcher and immunologist, dies at 84Research by Weizmann Institute scientist and Israel Prize winner saved 'countless lives,' was basis for technology sold for $12 billion in 2017 000
